

# **Transdermal Drug Delivery**

## **Technologies, Companies & Markets**

**By**

**Prof. K. K. Jain**  
MD, FRACS, FFPM  
**Jain PharmaBiotech**  
**Basel, Switzerland**

**November 2018**

**A Jain PharmaBiotech Report**

## **A B O U T   T H E   A U T H O R**

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain's 478 publications include 30 books (6 as editor + 24 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals.

Prof. Jain has edited "Drug Delivery Systems" (1<sup>st</sup> ed 2008, 2<sup>nd</sup> ed 2014, 3<sup>rd</sup> edn 2019, in preparation) and Drug Delivery to the Central Nervous System (2010), both published by Humana/Springer. His other recent books include "Handbook of Nanomedicine" (Springer/Humana 2008; Chinese ed, Peking University Press 2011, 2<sup>nd</sup> ed Springer 2012, 3<sup>rd</sup> ed 2017), "Textbook of Personalized Medicine (Springer 2009; Japanese ed 2012; 2<sup>nd</sup> ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2016, 2<sup>nd</sup> ed Springer 2017), "Application of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Application of Biotechnology in Neurology" (Springer 2013), and "Application of Biotechnology in Oncology" (Springer 2014)

## **A B O U T   T H I S   R E P O R T**

The original report on Transdermal Drug Delivery appeared as a section in the author's Drug Delivery Systems published by Decision Resources Inc in 1998. The second edition was published by Informa Pharmaceuticals after detaching Cancer Drug Delivery and Central Nervous System Drug Delivery as separate reports in 2000. In 2002, Transdermal Drug Delivery was also detached, expanded and updated to be issued as separate publications by Jain PharmaBiotech. The report was regularly updated since 2002, enlarged and rewritten for 2018 edition.

**November 2018**  
**Copyright © 2018 by**

**Jain PharmaBiotech**  
**Bläsiring 7**  
**CH-4057 Basel**  
**Switzerland**

**Tel & Fax:    +4161-6924461**  
**Email:        info@pharmabiotech.ch**  
**Web site:     http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

# TABLE OF CONTENTS

|  |           |
|--|-----------|
| <b>0. Executive Summary .....</b>  | <b>10</b> |
| <b>1. Basics of Transdermal Drug Delivery .....</b>                                      | <b>12</b> |
| <b>Introduction .....</b>  | <b>12</b> |
| Historical landmarks in transdermal drug delivery .....                                  | 12        |
| <b>Anatomy and physiology of skin .....</b>  | <b>13</b> |
| Skin metabolomics and transcutaneous passage of drugs.....                               | 13        |
| Transcutaneous absorption .....  | 14        |
| <b>Transdermal versus other methods of drug delivery.....</b>                            | <b>14</b> |
| Advantages of transdermal drug delivery .....  | 14        |
| <i>First-Pass Effect.....</i>  | <i>15</i> |
| Drawbacks of transdermal delivery.....   | 15        |
| <b>Factors that influence transdermal drug delivery .....</b>                            | <b>15</b> |
| Rate of permeation across the skin .....   | 16        |
| Properties of the skin .....   | 16        |
| Properties of drugs.....   | 17        |
| <i>The role of pH and pharmacokinetics .....</i>   | <i>18</i> |
| <i>Intradermal disposition of drugs after topical application.....</i>                   | <i>18</i> |
| Role of nanobiotechnology in understanding basis of transdermal delivery .....           | 18        |
| <b>2. Transdermal Drug Delivery Technologies .....</b>                                   | <b>20</b> |
| <b>Introduction .....</b>  | <b>20</b> |
| <b>Local application formulations .....</b>  | <b>21</b> |
| Crystalline topical formulations .....   | 21        |
| Microemulsions for transdermal drug delivery .....                                       | 21        |
| Nanoemulsions for transdermal drug delivery .....  | 22        |
| Transdermal gel technology .....   | 22        |
| Biphase system.....  | 24        |
| <b>Penetration enhancers.....</b>  | <b>24</b> |
| Chemical enhancers .....   | 24        |
| <i>Nitric oxide-based transdermal drug delivery.....</i>                                 | <i>26</i> |
| Ionic liquids for transdermal delivery of drugs against bacterial biofilms on skin ..... | 27        |
| Vesicular transdermal carriers .....   | 27        |
| <i>Liposomes.....</i>  | <i>27</i> |
| <i>Transfersomes.....</i>  | <i>28</i> |
| <i>Ethosomes.....</i>  | <i>28</i> |
| <i>Elastic vesicles for transdermal drug delivery .....</i>                              | <i>29</i> |
| <i>Nanovesicles for transdermal drug delivery .....</i>                                  | <i>29</i> |
| <b>Transdermal patches .....</b>   | <b>30</b> |
| Adhesives for transdermal patches.....   | 31        |
| Commercial development of transdermal patches .....                                      | 32        |
| Innovations in transdermal patches.....  | 32        |
| <i>e-Patch™ controlled release micropump system.....</i>                                 | <i>33</i> |
| <i>Patchless Transdermal Delivery System .....</i>                                       | <i>33</i> |
| <i>Metered-dose transdermal system .....</i>   | <i>34</i> |
| <b>Polymers for transdermal drug delivery.....</b>                                       | <b>34</b> |
| Polymer membranes in transdermal patches .....   | 35        |
| Film forming polymeric solutions.....  | 36        |
| Crystal Reservoir System of Nitto Denko .....  | 36        |
| <b>Use of physical modalities to facilitate transdermal transport .....</b>              | <b>37</b> |
| Transdermal electrotransport .....   | 37        |
| Electroporation .....  | 37        |
| <i>Drug delivery by electroporation .....</i>  | <i>38</i> |
| Cryoelectrophoresis.....   | 39        |
| Iontophoresis .....  | 40        |
| <i>Iontophoresis compared with electrophoresis .....</i>                                 | <i>40</i> |
| <i>Application of iontophoresis for drug delivery .....</i>                              | <i>40</i> |
| <i>Patents in iontophoresis.....</i>   | <i>42</i> |
| <i>Companies with technologies for drug delivery by iontophoresis .....</i>              | <i>42</i> |
| Combination of electrophoresis and iontophoresis .....                                   | 43        |
| <i>Dermaportation .....</i>  | <i>43</i> |
| Radiofrequency-driven transdermal delivery .....   | 44        |
| Microporation .....  | 44        |
| Transcutaneous drug delivery by electropulsation .....                                   | 44        |
| Companies involved in electroporation-based drug delivery .....                          | 45        |
| Electrode Scanning System .....  | 45        |
| Use of electrostatic force in skin patch technology.....                                 | 46        |

|   |           |
|---|-----------|
| Multiple Absorption Kinetic System.....   | 46        |
| Transdermal drug delivery facilitated by heat .....                               | 46        |
| <i>Controlled, heat-aided drug delivery</i> .....                                 | 46        |
| Ultrasound .....  | 47        |
| Magnetophoresis.....  | 48        |
| Use of lasers for transdermal drug delivery .....                                 | 49        |
| <i>Laser-induced microporation</i> .....  | 49        |
| <i>Transdermal drug delivery by laser-induced pressure waves</i> .....            | 49        |
| <i>Transdermal drug delivery by laser-assisted changes in skin</i> .....          | 50        |
| Transdermal delivery by gas under pressure .....                                  | 50        |
| <i>Transdermal delivery with PowderJect gas gun</i> .....                         | 50        |
| <i>Microscission induced by gas</i> .....   | 51        |
| <b>Role of microelectronics in transdermal drug delivery.....</b>                 | <b>51</b> |
| <b>Microneedles and dermal microinjection technologies.....</b>                   | <b>52</b> |
| Applications of microneedles .....  | 53        |
| AdminPatch® microneedle array.....  | 54        |
| Biodegradable microneedles.....   | 54        |
| Ceramic microneedle arrays .....  | 55        |
| Dissolvable microneedle patches.....  | 55        |
| MicorCor.....   | 55        |
| Microneedle arrays for drug delivery.....   | 56        |
| Microneedle patch.....  | 57        |
| MicroPyramid™ microneedles .....  | 57        |
| Microstructured Transdermal Systems .....   | 58        |
| Microneedle Array Patch technology .....  | 58        |
| Microneedle transdermal chip .....  | 59        |
| Microneedle applicator device.....  | 59        |
| Nanoject™ microneedle technology .....  | 59        |
| PatchPump.....  | 60        |
| Polymer microneedles .....  | 60        |
| Silk microneedles.....  | 61        |
| Tattooing for drug delivery.....  | 61        |
| ZP Patch microprojections technology.....   | 62        |
| Companies developing microneedles for transdermal drug delivery .....             | 62        |
| <b>Needlefree injections.....</b>   | <b>63</b> |
| Glide SDI® solid dose injector .....  | 63        |
| Jet injection .....   | 63        |
| Mini-Ject needlefree delivery system .....  | 63        |
| MicroJet for painless injections .....  | 64        |
| Nanoliter-volume pulsed microjets .....   | 64        |
| SUMAVEL™ DosePro™ needle-less injection .....                                     | 64        |
| <b>Skin ablation or abrasion for drug delivery.....</b>                           | <b>65</b> |
| <b>Nanotechnology-based transdermal drug delivery.....</b>                        | <b>65</b> |
| Delivery of nanostructured drugs from transdermal patches .....                   | 65        |
| Effect of mechanical flexion on penetration of bucky balls through the skin ..... | 66        |
| Nanobiotechnology for transdermal application .....                               | 66        |
| <i>Nanoparticles and nanoemulsions for skin disorders</i> .....                   | 66        |
| <i>Nanopatches</i> .....  | 67        |
| <i>Inocyte™ epidermal drug delivery system</i> .....                              | 67        |
| <i>Ionic nanoparticle technology</i> .....  | 67        |
| <i>SLN gel for treatment of skin disorders</i> .....                              | 68        |
| <i>Topical delivery of siRNA- nanoparticle conjugates</i> .....                   | 68        |
| <i>Transdermal nanoparticle preparations for systemic effect</i> .....            | 68        |
| <i>Transferosomes for transdermal drug delivery</i> .....                         | 69        |
| <i>Transdermal administration of nanocarriers</i> .....                           | 69        |
| Nanotechnology-based transdermal vaccination and immunotherapy.....               | 70        |
| Safety issues of applications of nanomaterial carriers on the skin.....           | 70        |
| <b>Comparison of transdermal drug delivery systems .....</b>                      | <b>70</b> |
| <b>Transdermal drug design .....</b>  | <b>71</b> |
| <b>In vitro testing of transdermal drug delivery systems .....</b>                | <b>71</b> |
| <i>Commercially available skin models for transdermal drug testing</i> .....      | 72        |
| <i>FDA guidelines for post-approval changes in semisolid topical drugs</i> .....  | 72        |
| <b>In vivo testing of drug delivery systems.....</b>                              | <b>73</b> |
| Infrared spectroscopy for evaluation of transdermal drug delivery.....            | 73        |
| <b>Modeling of transport through the skin.....</b>                                | <b>73</b> |
| <b>Concluding remarks on transdermal drug delivery technologies.....</b>          | <b>74</b> |
| <b>Future developments in transdermal drug delivery .....</b>                     | <b>74</b> |
| <b>3. Transdermal Therapeutics .....</b>  | <b>76</b> |
| <b>Introduction .....</b>   | <b>76</b> |
| <b>Drugs that can be administered transdermally .....</b>                         | <b>76</b> |

|   |            |
|---|------------|
| Approved transdermal products .....   | 76         |
| Drugs in clinical trials .....  | 78         |
| <b>Skin disorders.....</b>  | <b>79</b>  |
| Cutaneous leishmaniasis .....   | 79         |
| Hair loss .....   | 79         |
| Iontophoretic drug delivery for nail disorders.....                                 | 80         |
| Psoriasis .....   | 80         |
| <i>Nanoemulsions for paclitaxel delivery in psoriasis.....</i>                      | <i>80</i>  |
| <i>Iontophoresis for treatment of psoriasis.....</i>                                | <i>80</i>  |
| <b>Cardiovascular disorders .....</b>   | <b>81</b>  |
| Transdermal estrogen for prevention of atherosclerotic cardiovascular disease ..... | 81         |
| Transdermal drug delivery for angina pectoris .....                                 | 81         |
| Transdermal drug delivery for hypertension .....                                    | 82         |
| <i>Transdermal clonidine .....</i>  | <i>83</i>  |
| <i>Transdermal delivery of <math>\beta</math>-blockers for hypertension.....</i>    | <i>83</i>  |
| <i>Transdermal delivery of calcium channel blockers for hypertension .....</i>      | <i>84</i>  |
| Transdermal drug delivery for congestive heart failure.....                         | 84         |
| Transdermal beta blockers .....   | 84         |
| Transdermal anticoagulants .....  | 85         |
| <b>Respiratory diseases.....</b>  | <b>85</b>  |
| Asthma.....   | 85         |
| Chronic obstructive pulmonary disease .....   | 86         |
| <b>Neurological and psychiatric disorders .....</b>                                 | <b>87</b>  |
| Parkinson's disease .....   | 87         |
| <i>Transdermal drug delivery for Parkinson's disease .....</i>                      | <i>87</i>  |
| <i>Transdermal levodopa delivery systems.....</i>                                   | <i>87</i>  |
| <i>Transdermal dopamine agonists for Parkinson's disease.....</i>                   | <i>88</i>  |
| <i>Rotigotine for Parkinson disease .....</i>                                       | <i>89</i>  |
| <i>Rotigotine for restless legs syndrome .....</i>                                  | <i>91</i>  |
| <i>Transdermal administration of other drugs for Parkinson disease .....</i>        | <i>91</i>  |
| Depression.....   | 92         |
| <i>Antidepressants.....</i>   | <i>92</i>  |
| <i>Selective serotonin-reuptake inhibitors .....</i>                                | <i>92</i>  |
| <i>Transdermal fluoxetine.....</i>  | <i>93</i>  |
| <i>Monoamine oxidase inhibitors.....</i>  | <i>93</i>  |
| <i>Transdermal selegiline.....</i>  | <i>93</i>  |
| <i>Trazodone hydrochloride.....</i>   | <i>94</i>  |
| <i>Venlafaxine .....</i>  | <i>94</i>  |
| <i>Bupropion .....</i>  | <i>95</i>  |
| Bipolar disorder .....  | 95         |
| <i>Transdermal lithium .....</i>  | <i>95</i>  |
| Schizophrenia.....  | 96         |
| <i>Transdermal haloperidol .....</i>  | <i>96</i>  |
| <i>Transdermal risperidone for treatment of schizophrenia.....</i>                  | <i>96</i>  |
| <i>Transdermal blonanserin for treatment of schizophrenia .....</i>                 | <i>97</i>  |
| Restless legs syndrome .....  | 97         |
| Alzheimer's disease .....   | 97         |
| <i>Transdermal rivastigmine.....</i>  | <i>97</i>  |
| <i>Transdermal donepezil.....</i>   | <i>98</i>  |
| <i>Transdermal galantamine.....</i>   | <i>99</i>  |
| <i>Transdermal arecoline .....</i>  | <i>99</i>  |
| Transdermal nicotine for Tourette syndrome .....                                    | 99         |
| Attention deficit hyperactivity disorder.....                                       | 99         |
| <i>Transdermal methylphenidate .....</i>  | <i>99</i>  |
| Migraine .....  | 100        |
| <i>Transdermal sumatriptan .....</i>  | <i>100</i> |
| <i>Transdermal zolmitriptan .....</i>   | <i>101</i> |
| <i>Transdermal dihydroergotamine .....</i>  | <i>102</i> |
| Epilepsy.....   | 102        |
| Tinnitus/Vertigo.....   | 102        |
| Transdermal nitroglycerin for vasospasm due to subarachnoid hemorrhage.....         | 102        |
| <b>Musculoskeletal disorders.....</b>   | <b>103</b> |
| Osteoporosis .....  | 103        |
| <i>Transdermal alendronate .....</i>  | <i>103</i> |
| <i>Transdermal estrogen.....</i>  | <i>103</i> |
| <i>Transdermal human parathyroid hormone.....</i>                                   | <i>103</i> |
| Osteoarthritis .....  | 104        |
| <b>Transdermal therapy of diabetes .....</b>  | <b>104</b> |
| Insulin delivery in diabetes by transdermal patches.....                            | 104        |
| Microneedle patch for glucose-responsive insulin delivery .....                     | 105        |
| Patch monitoring system for insulin delivery.....                                   | 105        |

|   |            |
|---|------------|
| Sonic Applicator & Control Device for TDD of insulin .....                        | 106        |
| V-Go® disposable insulin delivery device .....                                    | 106        |
| ViaDor System for TDD of insulin .....  | 107        |
| Companies developing devices for transdermal insulin delivery .....               | 107        |
| Transdermal therapy of oral antidiabetic agents.....                              | 107        |
| <i>Transdermal antidiabetic agents other than insulin</i> .....                   | 108        |
| <b>Male disorders .....</b>   | <b>108</b> |
| Erectile dysfunction .....  | 108        |
| <i>Topical and transdermal preparation for erectile dysfunction</i> .....         | 109        |
| Hypogonadism in the male.....   | 109        |
| <i>Topical testosterone</i> .....   | 109        |
| Benign prostatic hypertrophy.....   | 111        |
| <i>Tamsulosin TDS</i> .....   | 111        |
| <b>Women's health .....</b>   | <b>111</b> |
| Female sexual arousal disorder.....   | 111        |
| Menopause.....  | 112        |
| <i>Hormone replacement therapy for menopause</i> .....                            | 112        |
| <i>Effect of transdermal estradiol on bone density</i> .....                      | 114        |
| <i>Transdermal PTH for postmenopausal osteoporosis</i> .....                      | 114        |
| <i>Transdermal testosterone for low libido in postmenopausal women</i> .....      | 115        |
| Breast disorders .....  | 115        |
| Dysmenorrhea.....   | 115        |
| Female infertility .....  | 116        |
| <b>Contraception .....</b>  | <b>116</b> |
| Female contraception .....  | 116        |
| <i>Ortho Evra™</i> .....  | 117        |
| <i>AG200-15</i> .....   | 117        |
| <i>BAY86-5016</i> .....   | 117        |
| <i>Desogestrel</i> .....  | 118        |
| Male contraception.....   | 118        |
| <i>Transdermal progestin plus testosterone</i> .....                              | 118        |
| <b>Cancer .....</b>   | <b>118</b> |
| Delivery of the photosensitizer drug $\delta$ -amino levulinic acid.....          | 118        |
| Intradermal delivery of cancer vaccines by adenoviral vectors .....               | 119        |
| Nanoemulsion-based delivery of caffeine for skin cancer.....                      | 119        |
| Topical interferon $\alpha$ 2b for cervical cancer and precancerous lesions ..... | 119        |
| Transcutaneous electroporation for delivery of anticancer drugs .....             | 120        |
| Transdermal delivery of peptide cancer vaccines.....                              | 120        |
| Transdermal drug delivery for prostate cancer.....                                | 120        |
| <i>Transdermal nitroglycerine for prostate cancer</i> .....                       | 120        |
| <i>Transdermal estradiol gel for prostate cancer</i> .....                        | 121        |
| <i>Transdermal leuprolide acetate for prostate cancer</i> .....                   | 121        |
| Transdermal drug delivery for breast cancer.....                                  | 121        |
| <i>Afimoxifene topical gel for breast cancer</i> .....                            | 121        |
| <b>Pain .....</b>   | <b>121</b> |
| Relief of pain associated with minor medical procedures .....                     | 122        |
| Transdermal lidocaine relief of postherpetic neuralgia .....                      | 122        |
| <i>Lidoderm®</i> .....  | 122        |
| <i>Lidopat®</i> .....   | 122        |
| <i>ZTlido</i> .....   | 122        |
| Transdermal capsaicin for relief of pain.....                                     | 123        |
| Nonsteroidal antiinflammatory drugs .....   | 123        |
| <i>Topical NSAIDs</i> .....   | 123        |
| <i>Transdermal ketoprofen</i> .....   | 124        |
| <i>Topical opioids</i> .....  | 125        |
| Cancer pain.....  | 125        |
| <i>Transdermal fentanyl</i> .....   | 125        |
| <i>Transdermal nitroglycerine as an adjuvant to opioids</i> .....                 | 126        |
| <i>Transdermal buprenorphine</i> .....  | 126        |
| Chronic pain of non-malignant origin .....  | 127        |
| Transdermal local anesthetics.....  | 127        |
| Postoperative pain .....  | 127        |
| <i>Transdermal fentanyl for the management of postoperative pain</i> .....        | 127        |
| <i>Fibromyalgia</i> .....   | 128        |
| Nanotechnology-based approved transdermal analgesic preparations .....            | 128        |
| <b>Nausea and vomiting .....</b>  | <b>128</b> |
| Motion sickness .....   | 128        |
| Postoperative vomiting .....  | 128        |
| Chemotherapy-induced nausea and vomiting .....                                    | 129        |
| <b>Antiaging strategies .....</b>   | <b>129</b> |
| <b>Smoking cessation .....</b>  | <b>130</b> |

|  |            |
|--|------------|
| Transdermal nicotine replacement.....  | 130        |
| Use of nicotine patch for smoking cessation in pregnancy .....                   | 130        |
| Other methods of nicotine replacement .....                                      | 131        |
| Other treatments for smoking cessation.....                                      | 131        |
| <b>Miscellaneous uses of transdermal drug delivery.....</b>                      | <b>131</b> |
| Allergic rhinitis.....   | 131        |
| Chronic fatigue syndrome .....   | 132        |
| Overactive bladder and urinary incontinence .....                                | 132        |
| <i>Transdermal oxybutynin .....</i>  | <i>132</i> |
| Viral infections.....  | 133        |
| <i>Transdermal nanoparticles for immune enhancement in HIV.....</i>              | <i>133</i> |
| <i>Transdermal IQP-0410 for HIV/AIDS .....</i>                                   | <i>134</i> |
| Wound healing and ulcers .....   | 134        |
| <b>Transdermal gene therapy .....</b>  | <b>135</b> |
| Transdermal delivery of plasmid DNA by electroporation .....                     | 135        |
| <b>Transdermal antisense therapy .....</b>                                       | <b>135</b> |
| <b>Transdermal vaccination.....</b>  | <b>136</b> |
| The skin as an immune organ.....   | 136        |
| Technologies for transdermal vaccination.....                                    | 136        |
| <i>Dissolvable microneedle array for vaccine delivery .....</i>                  | <i>137</i> |
| <i>Electroporation for administering DNA vaccines .....</i>                      | <i>137</i> |
| <i>Microneedles for transdermal delivery of vaccines .....</i>                   | <i>138</i> |
| <i>Needle-free delivery of vaccines.....</i>                                     | <i>139</i> |
| <i>Transcutaneous immunotherapy using nanodispersions .....</i>                  | <i>140</i> |
| Applications of transdermal vaccination .....                                    | 141        |
| <i>HIV/AIDS vaccination by topical application.....</i>                          | <i>141</i> |
| <i>Transdermal DNA influenza vaccine.....</i>                                    | <i>142</i> |
| <i>Transdermal A<math>\beta</math> vaccination for Alzheimer's disease .....</i> | <i>142</i> |
| <i>Transdermal vaccination for traveller's diarrhoea .....</i>                   | <i>142</i> |
| <b>Transdermal nutraceuticals .....</b>  | <b>143</b> |
| <b>Complications of transdermal therapy .....</b>                                | <b>143</b> |
| Adverse effects of drugs .....   | 143        |
| Overdose effect .....  | 144        |
| Skin complications .....   | 144        |
| <i>MRI-induced skin burns from transdermal patches .....</i>                     | <i>144</i> |
| <b>4. Markets for Transdermal Drug Delivery .....</b>                            | <b>146</b> |
| <b>Introduction .....</b>  | <b>146</b> |
| <b>Global markets for drug delivery .....</b>                                    | <b>146</b> |
| <b>Geographical distribution of transdermal drug delivery markets .....</b>      | <b>147</b> |
| Emerging transdermal drug delivery markets in Asia .....                         | 147        |
| <b>Transdermal technology markets in therapeutic areas .....</b>                 | <b>147</b> |
| Angina pectoris.....   | 148        |
| Attention deficit hyperactivity disorder.....                                    | 148        |
| Erectile dysfunction.....  | 149        |
| Hypertension.....  | 149        |
| Osteoporosis .....   | 149        |
| Pain therapeutics .....  | 149        |
| Parkinson's disease .....  | 149        |
| Smoking cessation .....  | 150        |
| Transdermal hormone replacement therapy for menopause .....                      | 150        |
| Transdermal testosterone replacement therapy for hypogonadism in the male .....  | 150        |
| Transdermal contraceptive market .....   | 150        |
| <b>Markets according to transdermal technologies.....</b>                        | <b>151</b> |
| Markets for microneedle-based transdermal drug delivery.....                     | 151        |
| <b>Marketing strategies for transdermal drug delivery.....</b>                   | <b>151</b> |
| <b>Marketing advantages of transdermal drug delivery.....</b>                    | <b>152</b> |
| <b>Unmet needs in transdermal drug delivery .....</b>                            | <b>152</b> |
| <b>Regulatory aspects that affect transdermal drug delivery markets.....</b>     | <b>153</b> |
| <b>Future prospects of transdermal drug delivery .....</b>                       | <b>154</b> |
| Growth of new technologies used in transdermal drug delivery .....               | 154        |
| Prospects of transdermal delivery for drugs coming off patents.....              | 154        |
| Transdermal delivery of biologicals.....   | 155        |
| Transdermal delivery of cosmetics .....  | 155        |
| <b>5. Companies involved in transdermal drug delivery .....</b>                  | <b>156</b> |
| <b>Profiles of companies.....</b>  | <b>156</b> |
| <b>Collaborations.....</b>   | <b>284</b> |
| <b>6. References.....</b>  | <b>288</b> |

## Tables

|   |     |
|---|-----|
| Table 1-1: Historical landmarks in the development of transdermal drug delivery .....   | 12  |
| Table 1-2: Transdermal vs oral and intravenous drug delivery .....                      | 14  |
| Table 1-3: Size ranges of molecules that can be delivered by transdermal route.....     | 17  |
| Table 2-1: Technologies for transdermal drug delivery .....                             | 20  |
| Table 2-2: Chemical enhancers of skin penetration .....                                 | 25  |
| Table 2-3: Drug-in-adhesive versus reservoir type of transdermal patch.....             | 30  |
| Table 2-4: Companies with transdermal patches for drug delivery.....                    | 32  |
| Table 2-5: Companies with technologies for drug delivery by iontophoresis.....          | 42  |
| Table 2-6: Companies involved in electroporation-based drug delivery .....              | 45  |
| Table 2-7: Companies developing microneedles for transdermal drug delivery.....         | 62  |
| Table 2-8: Comparison of transdermal drug delivery systems.....                         | 71  |
| Table 3-1: Approved transdermal products .....  | 76  |
| Table 3-2: Transdermal drugs in clinical trials or approval process .....               | 78  |
| Table 3-3: Companies developing devices for transdermal insulin delivery .....          | 107 |
| Table 3-4: Selected transdermal systems GLP-1 antidiabetic agents.....                  | 108 |
| Table 4-1: Worldwide drug delivery market growth 2017 to 2027 .....                     | 146 |
| Table 4-2: Transdermal drug delivery markets for geographical regions 2017 to 2027..... | 147 |
| Table 4-3: Markets for transdermal products for therapeutic areas 2017-2027 .....       | 148 |
| Table 4-4: Markets according to transdermal technologies 2017-2027.....                 | 151 |
| Table 4-5: Marketing strategies based on transdermal drug delivery technologies.....    | 151 |
| Table 5-1: Top ten companies in transdermal drug delivery .....                         | 156 |
| Table 5-2: Collaborations in transdermal drug delivery .....                            | 284 |

## Figures

|   |     |
|---|-----|
| Figure 1-1: Basic structure of the skin.....  | 13  |
| Figure 1-2: Passages of transcutaneous drug absorption .....                              | 14  |
| Figure 1-3: Events governing transcutaneous drug absorption .....                         | 16  |
| Figure 2-1: Basic structure and function of transdermal drug delivery systems.....        | 30  |
| Figure 2-2: Transdermal system for delivery of liquid drugs .....                         | 31  |
| Figure 2-3: Crystal Reservoir System of Nitto Denko .....                                 | 36  |
| Figure 2-4: A schematic view of electroporation.....                                      | 37  |
| Figure 2-5: Depiction of breakdown of the stratum corneum during electroporation .....    | 39  |
| Figure 2-6: A schematic drawing of Iontophoresis.....                                     | 40  |
| Figure 2-7: SonoPrep ultrasonic skin permeation .....                                     | 48  |
| Figure 2-8: A a schematic sketch of PowderJect gas gun.....                               | 51  |
| Figure 2-9: Drug delivery using different types of microneedles (MN) .....                | 52  |
| Figure 2-10: A schematic drawing of the microneedle patch .....                           | 57  |
| Figure 2-11: Preparation of solid-in-oil nanodispersion for transdermal application.....  | 66  |
| Figure 3-1: Oral versus transdermal administration of a drug in Parkinson's disease ..... | 90  |
| Figure 3-2: Control functions and user interface of insulin patch monitoring system.....  | 106 |
| Figure 3-3: Transcutaneous immunotherapy using nanodispersions .....                      | 141 |
| Figure 4-1: Unmet needs in transdermal drug delivery .....                                | 153 |